Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Lilly Cuts 3,500 Jobs Globally To Drive Growth

Executive Summary

Lilly will save $500m annually starting in 2018 after $1.2bn in layoff-related costs to reinvest in new products. Also, Cytori halves its headcount; VC OrbiMed closed a $551m Asia fund; and Insmed capitalizes on positive data.

Advertisement

Related Content

Pipeline Watch: Phase III Starts With Fasinumab, Varlitinib
Lilly Hopes To Revitalize Its Cancer Brand With 'Foundational' Agents
BIO Notebook, Day 3: Lilly Expands R&D Site, Sigilon Raises Cash And CytomX Talks Deal Strategy
Lilly Breathing Down Amgen/Novartis's Necks With Three Phase III Migraine Wins
Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market
Lilly Shows Diabetes Dominance, But Will It Last?
Lilly CEO ‘Encouraged’ By Trump Meeting As Volume – Not Prices – Drives 4Q Revenue Growth
BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim
Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success
Limited Japan Nod For Cytori’s Osteoarthritis Cell Therapy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099448

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel